gazyva 1000 mg concentrat pentru soluţie perfuzabilă
f.hoffmann-la roche ltd - obinutuzumabum - concentrat pentru soluţie perfuzabilă - 1000 mg
mylotarg
wyeth europa ltd - gemtuzumab ozogamicin - leucemie, mieloidă, acută - agenți antineoplazici - re-tratamentul de inducție cd33-pozitiv aml pacienții adulți în prima recădere care nu sunt candidați pentru alte intensiv de re-chimioterapie de inducție regimuri (e. doze mari de ara-c) și să îndeplinească cel puțin unul din următoarele criterii: durata de prima remisiune 60 de ani.
mylotarg 5 mg
pfizer ireland pharmaceuticals - irlanda - gemtuzumab ozogamicin - pulb. pt. conc. pt. sol. perf. - 5mg - anticorpi monoclonali alti anticorpi monoclonali si conjugati anticorp medicament
perjeta 420mg
roche pharma ag - germania - pertuzumabum - conc. pt. sol. perf. - 420mg - anticorpi monoclonali
besponsa 1 mg
pfizer ireland pharmaceuticals - irlanda - inotuzumab ozogamicin - pulb. pt. conc. pt. sol. perf. - 1mg - anticorpi monoclonali si conjugati anticorp medicament
perjeta 420 mg concentrat pentru soluţie perfuzabilă
f.hoffmann-la roche, ltd. - pertuzumabum - concentrat pentru soluţie perfuzabilă - 420 mg
gazyvaro 1000 mg
roche pharma ag - germania - obinutuzumabum - conc. pt. sol. perf. - 1000mg - anticorpi monoclonali si conjugati anticorp medicament
bendamustina kabi 2,5 mg/ml
fresenius kabi deutschland gmbh - germania - bendamustinum - pulb. pt. conc. pt. sol. perf. - 2,5mg/ml - agenti alchilanti analogi de nitrogen mustard
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leucemie, limfocitică, cronică, celule b - agenți antineoplazici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
phesgo 1200 mg/600 mg
roche pharma ag - germania - combinatii (pertuzumabum+trastuzumabum) - sol. inj. - 1200mg/600mg - alte antineoplazice alte antineoplazice in combinatie